Myopodin methylation is associated with clinical outcome in patients with T1G3 bladder cancer

Journal of Urology

Volumn 184, Issue 4, 2010, Pages 1507-1513

  Alvarez Múgica, Miguel ^a,b   Cebrian, Virginia ^a   Fernández Gómez, Jesus M ^b   Fresno, Florentino ^b   Escaf, Safwan ^b   Sánchez Carbayo, Marta ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

methylation; Mycobacterium bovis; SYNPO2 protein, human; urinary bladder; urinary bladder neoplasms

Indexed keywords

BCG VACCINE; MYOPODIN; TUMOR MARKER; UNCLASSIFIED DRUG; ACTIN BINDING PROTEIN; IMMUNOLOGICAL ADJUVANT; SYNPO2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER INVASION; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; DISEASE COURSE; EPIGENETICS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN METHYLATION; RECURRENCE RISK; UNIVARIATE ANALYSIS; CANCER STAGING; METABOLISM; METHYLATION; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; VERY ELDERLY;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; AGED, 80 AND OVER; BCG VACCINE; FEMALE; HUMANS; MALE; METHYLATION; MICROFILAMENT PROTEINS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 79961003963     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2010.05.085     Document Type: Article

References (30)

1. A. Jemal, R. Siegel, and E. Ward Cancer statistics, 2008 CA Cancer J Clin 58 2008 71
2. M. Sanchez-Carbayo, and C. Cordon-Cardo Molecular alterations associated with bladder cancer progression Semin Oncol 34 2007 75
3. A. Morales, D. Eideger, and A.W. Bruce Intracavitary bacillus Calmette-Guerin in the superficial bladder tumor J Urol 116 1976 180
4. D.L. Lamm Preventing progression and improving survival with BCG maintenance Eur Urol 1 2000 9
5. J.J. Patard, A. Rodriguez, and E. Leary Intravesical bacillus Calmette Guerin treatment improves patient survival in T1G3 bladder tumors Eur Urol 41 2002 635
6. F. Saint, L. Salomon, and R. Quintela Do prognostic parameters of remission versus relapse after bacillus Calmette-Guerin (BCG) immunotherapy exist? Analysis of a quarter century of literature Eur Urol 43 2003 351
7. R.J. Sylvester, A.P. van derMeijden, and W. Oosterlinck Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials Eur Urol 49 2006 466
8. J. Fernandez-Gomez, E. Solsona, and M. Unda Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Gurin: multivariate analysis of data from four randomized CUETO trials Eur Urol 53 2008 992
9. F. Millan-Rodriguez, G. Chechile-Toniolo, and J. Salvador-Bayarri Primary superficial bladder cancer risk groups according to progression, mortality and recurrence J Urol 163 2000 680
10. E. Solsona, I. Iborra, and R. Dumont The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer J Urol 164 2000 685
11. J. Palou, O. Rodriguez, and J. Segarra Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy J Urol 176 2006 407
12. V. Cebrian, M. Alvarez, and A. Aleman Discovery of myopodin methylation in bladder cancer J Pathol 216 2008 111
13. A. Weins, K. Schwarz, and C. Faul Differentiation- and stress-dependent nuclear cytoplasmic redistribution of myopodin, a novel actin-bundling protein J Cell Biol 155 2001 393
14. K. Van Impe, V. De Corte, and L. Eichinger The Nucleo-cytoplasmic actin-binding protein CapG lacks a nuclear export sequence present in structurally related proteins J Biol Chem 278 2003 17945
15. F. Lin, Y.P. Yu, and J. Woods Myopodin, a synaptopodin homologue, is frequently deleted in invasive prostate cancers Am J Pathol 159 2001 1603
16. L. Jing, L. Liu, and Y.P. Yu Expression of myopodin induces suppression of tumor growth and metastasis Am J Pathol 164 2004 1799
17. Y.P. Yu, and J.H. Luo Myopodin-mediated suppression of prostate cancer cell migration involves interaction with zyxin Cancer Res 66 2006 7414
18. Y.P. Yu, G.C. Tseng, and J.H. Luo Inactivation of myopodin expression associated with prostate cancer relapse Urology 68 2006 578
19. M. Snchez-Carbayo, K. Schwarz, and E. Charytonowicz Tumor suppressor role for myopodin in bladder cancer: loss of nuclear expression of myopodin is cell-cycle dependent and predicts clinical outcome Oncogene 22 2003 5298
20. C. Faul, S. Httelmaier, and J. Oh Promotion of import alpha-mediated nuclear import by the phophorylation-dependent binding of cargo protein to 14-3-3 J Cell Biol 169 2005 415
21. A. De Ganck, T. Hubert, and K. Van Impe A monopartite nuclear localization sequence regulates nuclear targeting of the actin binding protein myopodin FEBS Lett 579 2005 6673
22. C. Faul, A. Dhume, and A.D. Schecter Protein kinase A, Ca2+/calmodulin-dependent kinase II, and calcineurin regulate the intracellular trafficking of myopodin between the Z-disc and the nucleus of cardiac myocytes Mol Cell Biol 27 2007 8215
23. J. Liang, G. Ke, and W. You Interaction between importin 13 and myopodin suggests a nuclear import pathway for myopodin Mol Cell Biochem 307 2008 93
24. J.I. Epstein, M.B. Amin, and V.R. Reuter The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder Bladder Consensus Conference Committee Am J Surg Pathol 22 1998 1435
25. M. Sanchez-Carbayo, N.D. Socci, and J. Lozano Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays J Clin Oncol 24 2006 778
26. A. Aleman, L. Adrien, and L. Lopez-Serra Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays Br J Cancer 98 2008 466
27. B. Dawson-Saunders, and R.G. Trapp Basic and Clinical Biostatistics 2nd ed. 1994 Appleton & Lange Norwalk, Connecticut
28. H.T. Kim Cumulative incidence in competing risks data and competing risks regression analysis Clin Cancer Res 13 2007 559
29. P.K. Ruan, and R.J. Gray Analyses of cumulative incidence functions via non-parametric multiple imputation Stat Med 27 2008 5709
30. R.J. Caplan, T.F. Pajak, and J.D. Cox Analysis of the probability and risk of cause-specific failure Int J Radiat Oncol Biol Phys 29 1994 1183